1.83 USD
▲+0.10+12.96%
盘后 1.65 +1.85%
2026-08-03
市值
$13.80M
市盈率
—
EPS
-3.49
股息率
—
52 周区间
1.06 – 6.15
成交量
397.68K
Beta
0.57
目标价
5.26
52W 低 1.0652W 高 6.15
价格走势
公司简介
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease; and in Phase 2 clinical trial to treat Parkinson’s disease, as well as for the long COVID program. The company was formerly...